Merck KGaA plans to acquire SpringWorks Therapeutics (NASDAQ:SWTX) for approximately $3.9 billion, aiming to enhance its ...

NEW YORK (AP) — U.S. stocks are drifting in mixed trading Tuesday as stronger-than-expected profits keep piling higher for ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

AstraZeneca on Tuesday said it had received an opinion from authorities in Shenzhen city of suspected unpaid import taxes of ...

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...

Fintel reports that on April 28, 2025, Barclays downgraded their outlook for SpringWorks Therapeutics (NasdaqGS:SWTX) from ...

The loans sat on banks' books for two-and-a-half years until the election of Donald Trump rapidly changed the company's fortunes. International Business Machines plans to invest $150 billion in the ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

HOUSTON (AP) — HOUSTON (AP) — NOV Inc. (NOV) on Monday reported first-quarter earnings of $73 million. On a per-share basis, the Houston-based company said it had profit of 19 cents. The results fell ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Health-care companies rose amid deal activity. Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology ...

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...